Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism

Sorafenib is used as first line treatment of renal cell carcinoma (RCC) due to the poor sensitivity to radiotherapy and chemotherapy of this malignancy; however, acquired resistance limits the application of sorafenib and its analogues. In this study, we explored a new strategy to overcome acquired...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Liu, Shuai, Gao, Mingwei, Wang, Xiaoqing, Ding, Sentai, Lv, Jiaju, Gao, Dexuan, Wang, Zhiyang, Niu, Zhihong
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346704/
https://ncbi.nlm.nih.gov/pubmed/27816967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados